Chromosome arm-specific long telomeres: A new clonal event in primary chronic myelogenous leukemia cells

Neoplasia

Volumn 13, Issue 6, 2011, Pages 550-560

  Samassekou, Oumar ^a   Li, Huiyu ^b   Hébert, Josée ^c,d   Ntwari, Aimé ^a   Wang, Haixia ^b   Cliché, Catherine Grenier ^a   Bouchard, Eric ^a   Huang, Shiang ^b   Yan, Ju ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PEPTIDE NUCLEIC ACID;

ARTICLE; CANCER PATIENT; CHROMOSOME 11P; CHROMOSOME 13P; CHROMOSOME 13Q; CHROMOSOME 14P; CHROMOSOME 15P; CHROMOSOME 18P; CHROMOSOME 4Q; CHROMOSOME 5P; CHROMOSOME 7Q; CHROMOSOME ARM; CHROMOSOME XP; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TELOMERE;

EID: 79958132757     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11358     Document Type: Article

References (53)

1. Ancelin K, Brun C, and Gilson E (1998). Role of the telomeric DNA-binding protein TRF2 in the stability of human chromosome ends. Bioessays 20, 879-883.
2. Blackburn EH (2005). Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 579, 859-862.
3. Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst P, and de Lange T (1995). A human telomeric protein. Science 270, 1663-1667.
4. Gilson E and Segal-Bendirdjian E (2010). The telomere story or the triumph of an open-minded research. Biochimie 92, 321-326.
5. van Steensel B, Smogorzewska A, and de Lange T (1998). TRF2 protects human telomeres from end-to-end fusions. Cell 92, 401-413.
6. Watson JD (1972). Origin of concatemeric T7 DNA. Nat New Biol 239, 197-201.
7. Hayflick L and Moorhead PS (1961). The serial cultivation of human diploid cell strains. Exp Cell Res 25, 585-621.
8. Olovnikov AM (1973). A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 41, 181-190.
9. Shay JW and Roninson IB (2004). Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23, 2919-2933.
10. Shay JW and Wright WE (2010). Telomeres and telomerase in normal and cancer stem cells. FEBS Lett 584, 3819-3825.
11. Cristofari G and Lingner J (2006). The telomerase ribonucleoprotein particle. In Telomeres (2nd ed). T de Lang, V Lundblad, and E Blackburn (Eds). John Inglis, New York, NY. pp. 21-47.
12. Shay JW and Bacchetti S (1997). A survey of telomerase activity in human cancer. Eur J Cancer 33, 787-791.
13. Greider CW (1998). Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci USA 95, 90-92.
14. Shay JW and Wright WE (2006). Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 5, 577-584.
15. Ohyashiki JH, Sashida G, Tauchi T, and Ohyashiki K (2002). Telomeres and telomerase in hematologic neoplasia. Oncogene 21, 680-687.
16. Boultwood J, Fidler C, Shepherd P, Watkins F, Snowball J, Haynes S, Kusec R, Gaiger A, Littlewood TJ, Peniket AJ, et al. (1999). Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. Am J Hematol 61, 5-9.
17. Brummendorf TH and Balabanov S (2006). Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia 20, 1706-1716.
18. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, and Moore MA (2000). Telomerase activity and telomere length in acute and chronic leukemia, pre-and post-ex vivo culture. Cancer Res 60, 610-617.
19. Terasaki Y, Okumura H, Ohtake S, and Nakao S (2002). Accelerated telomere length shortening in granulocytes: a diagnostic marker for myeloproliferative diseases. Exp Hematol 30, 1399-1404.
20. Martens UM, Zijlmans JM, Poon SS, DragowskaW, Yui J, Chavez EA, Ward RK, and Lansdorp PM (1998). Short telomeres on human chromosome 17p. Nat Genet 18, 76-80.
21. Londono-Vallejo JA, DerSarkissian H, Cazes L, and Thomas G (2001). Differences in telomere length between homologous chromosomes in humans. Nucleic Acids Res 29, 3164-3171.
22. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, et al. (2002). Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 99, 12606-12611.
23. Perrem K, Colgin LM, Neumann AA, Yeager TR, and Reddel RR (2001). Coexistence of alternative lengthening of telomeres and telomerase in hTERTtransfected GM847 cells. Mol Cell Biol 21, 3862-3875.
24. Desmaze C, Soria JC, Freulet-Marriere MA, Mathieu N, and Sabatier L (2003). Telomere-driven genomic instability in cancer cells. Cancer Lett 194, 173-182.
25. Slijepcevic P (1998). Telomere length regulation-a view from the individual chromosome perspective. Exp Cell Res 244, 268-274.
26. Cristofari G and Lingner J (2006). Telomere length homeostasis requires that telomerase levels are limiting. EMBO J 25, 565-574.
27. Hug N and Lingner J (2006). Telomere length homeostasis. Chromosoma 115, 413-425.
28. Britt-Compton B, Capper R, Rowson J, and BairdDM (2009). Short telomeres are preferentially elongated by telomerase in human cells. FEBS Lett 583, 3076-3080.
29. Rowley JD (1973). Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293.
30. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355, 2408-2417.
31. Lansdorp PM, Verwoerd NP, van de Rijke FM, Dragowska V, Little MT, Dirks RW, Raap AK, and Tanke HJ (1996). Heterogeneity in telomere length of human chromosomes. Hum Mol Genet 5, 685-691.
32. Yan J, Chen BZ, Bouchard EF, and Drouin R (2004). The labeling efficiency of human telomeres is increased by double-strand PRINS. Chromosoma 113, 204-209.
33. ISCN (2009). In An International System for Human Cytogenetic Nomenclature. L Shaffer, M Slovak, and L Campbell (Eds). S. Karger, Basel, Switzerland.
34. McClave J, Dietrich F, and Sincich T (1997). Statistics. Prentice-Hall, Inc., Englewood Cliffs, NJ.
35. Dewald G, Stallard R, Al Saadi A, Arnold S, Bader PI, Blough R, Chen K, Elejalde BR, Harris CJ, Higgins RR, et al. (1998). A multicenter investigation with interphase fluorescence in situ hybridization using X-and Y-chromosome probes. Am J Med Genet 76, 318-326.
36. Samassekou O, Ntwari A, Hebert J, and Yan J (2009). Individual telomere lengths in chronic myeloid leukemia. Neoplasia 11, 1146-1154.
37. Graakjaer J, Bischoff C, Korsholm L, Holstebroe S, Vach W, Bohr VA, Christensen K, and Kolvraa S (2003). The pattern of chromosome-specific variations in telomere length in humans is determined by inherited, telomere-near factors and is maintained throughout life. Mech Ageing Dev 124, 629-640.
38. Xing J, Ajani JA, Chen M, Izzo J, Lin J, Chen Z, Gu J, and Wu X (2009). Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev Res (Phila) 2, 459-465.
39. TeixeiraMT, ArnericM, Sperisen P, and Lingner J (2004). Telomere length homeostasis is achieved via a switch between telomerase-extendible and-nonextendible states. Cell 117, 323-335.
40. Zhu L, Hathcock KS, Hande P, Lansdorp PM, Seldin MF, and Hodes RJ (1998). Telomere length regulation in mice is linked to a novel chromosome locus. Proc Natl Acad Sci USA 95, 8648-8653.
41. Lyon MF (1961). Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 190, 372-373.
42. Surralles J, Hande MP, Marcos R, and Lansdorp PM (1999). Accelerated telomere shortening in the human inactive X chromosome. Am J Hum Genet 65, 1617-1622.
43. Shay JWandWright WE (2000). Implications of mapping the human telomerase gene (hTERT) as the most distal gene on chromosome 5p. Neoplasia 2, 195-196.
44. Bryce LA, Morrison N, Hoare SF, Muir S, and Keith WN (2000). Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization. Neoplasia 2, 197-201.
45. Johnson E and Cotter FE (1997). Monosomy 7 and 7q-associated with myeloid malignancy. Blood Rev 11, 46-55.
46. De Braekeleer E, Meyer C, Douet-Guilbert N, Morel F, Le Bris MJ, Berthou C, Arnaud B, Marschalek R, Ferec C, and De Braekeleer M (2010). Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature. Blood Cells Mol Dis 44, 268-274.
47. Yan J, Whittom R, Delage R, and Drouin R (2003). A unique clone involving multiple structural chromosome rearrangements in a myelodysplastic syndrome case. Cancer Genet Cytogenet 140, 138-144.
48. Yan J, Zhang XX, Fetni R, and Drouin R (2001). Trisomy 8 and monosomy 7 detected in bone marrow using primed in situ labeling, fluorescence in situ hybridization, and conventional cytogenetic analyses. A study of 54 cases with hematological disorders. Cancer Genet Cytogenet 125, 30-40.
49. Krejci K, Stentoft J, and Koch J (1999). Molecular cytogenetics investigation of the telomeres in a case of Philadelphia positive B-ALL with a single telomere expansion. Neoplasia 1, 492-497.
50. Lange K, Holm L, Vang Nielsen K, Hahn A, Hofmann W, Kreipe H, Schlegelberger B, and Gohring G (2010). Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 49, 260-269.
51. INK4a. Mol Cell 14, 501-513.
52. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, and Jackson SP (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198.
53. Zou Y, Sfeir A, Gryaznov SM, Shay JW, and Wright WE (2004). Does a sentinel or a subset of short telomeres determine replicative senescence? Mol Biol Cell 15, 3709-3718.